On January 19, 2024, the selection activity for "2023 Shandong Socially Responsible Enterprises (Entrepreneurs)" concluded, with Qidu Pharma being honored as a "2023 Shandong Socially Responsible Enterprise."
Since its establishment, especially after its restructuring in 1998, Qidu Pharma has consistently adhered to the principles of developing the enterprise, ensuring employee well-being, and giving back to society, delivering outstanding results. Firstly, the company actively practices green, low-carbon, and high-quality development. It is committed to leading the industry's digital transformation by continuously introducing advanced intelligent equipment and applying next-generation information technologies. The company has completed and put into operation an annual production project of 1.2 billion bottles/bags of new infusion solutions, achieving a comprehensive energy-saving rate of over 30%. This results in annual savings of 6,000 tons of steam, 75,000 tons of raw water, and 3.55 million kWh of electricity, while reducing carbon dioxide emissions by 9,400 tons. Qidu Pharma pioneered the green enzymatic synthesis process for levocarnitine API in China, resolving the issues of high risk and high pollution in the production process, breaking technological monopolies, and filling a domestic gap. The company has invested over RMB 50 million to upgrade VOCs waste gas treatment facilities, expand wastewater treatment systems, and renovate rain-sewage diversion systems, promoting green and coordinated development. Secondly, the company has implemented multiple measures to enhance employee happiness. It has invested more than RMB 14 million in comprehensive care programs covering weddings and funerals, childcare services, poverty alleviation, and protection of female employees' rights, ensuring both new and long-serving employees share in the fruits of development and experience tangible improvements in well-being. Qidu Pharma has established mechanisms such as internal open recruitment and selection of young reserve cadres, providing employees with open, fair, and equitable platforms for growth and development. In recent years, despite challenges posed by the COVID-19 pandemic and economic downturns, the company has maintained an annual salary increase rate of over 10%. Thirdly, Qidu Pharma actively participates in public welfare initiatives to give back to society. The company has established multiple volunteer teams, including Party and League members as well as "Compassion Ambassadors," who regularly carry out activities such as urban clean-ups, caring for elderly individuals living alone, and providing medical consultation services. The company has made numerous donations in response to disasters such as the Wenchuan earthquake, Yushu earthquake, and Shouguang floods, and has contributed over RMB 10 million to support education. As a vanguard in Shandong-Chongqing poverty alleviation cooperation, Qidu Pharma donated more than RMB 2 million and supported poverty relief projects through practical actions, purchasing tens of thousands of kilograms of agricultural products annually through consumption-based poverty alleviation initiatives, aiding Shizhu County in Chongqing to overcome poverty. Since the outbreak of COVID-19, while ensuring stable drug supply, the company has donated over RMB 10 million in funds and supplies to disaster-stricken areas, local governments, enterprises, and public institutions, contributing significantly to the fight against the pandemic.
Looking ahead, Qidu Pharma will continue to uphold its mission of "Creating Value and Serving the Nation Through Industry," bearing responsibility in heart, shouldering responsibility in action, and fulfilling responsibility through practice. The company will deeply integrate national needs, public expectations, and its own capabilities, effectively playing an exemplary role and undertaking more social responsibilities. Through high-quality development, Qidu Pharma aims to drive continuous progress in local economic and social development as well as the national pharmaceutical and healthcare sector.
